A simultaneous FGFR1/CCND1 amplification and synergistic inhibition of tumor growth occur in ER+ breast cancer cells deprived of estrogen when palbociclib is combined with an FGFR inhibitor [90]. Here, CCND1 is linked to breast cancer.